Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study

低剂量替奈普酶与标准剂量阿替普酶治疗急性缺血性中风：一项基于影像学的安全性和有效性研究

• 批准号: nhmrc : 510722
• 负责人: A/Pr Romesh Markus
• 金额: $ 23.29万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/low-dose-tenecteplase-efficacy-study/78429
• 关键词: Low; Dose; Tenecteplase; vs; Standard

This study compares standard dose alteplase (a proven stroke thrombolytic) with a low dose of the new medication tenecteplase for stroke treatment. We propose that the clot-dissolving activity of low-dose tenecteplase will be superior to alteplase, with a lower risk of brain bleeding. MRI scanning is the most effective way of assessing outcomes and will be used to measure how well the medication restores blood flow, the amount of permanent brain damage, and whether any brain bleeding occurs.

本研究比较了标准剂量的阿替普酶（一种已证实的卒中溶栓药物）与低剂量的新药替奈普酶治疗卒中。我们认为低剂量替奈普酶的溶栓活性上级阿替普酶，脑出血风险较低。MRI扫描是评估结果的最有效方法，将用于测量药物恢复血流的程度，永久性脑损伤的程度以及是否发生任何脑出血。